Author:
Vacharathit Vimvara,Aiewsakun Pakorn,Manopwisedjaroen Suwimon,Srisaowakarn Chanya,Laopanupong Thanida,Ludowyke Natali,Phuphuakrat Angsana,Setthaudom Chavachol,Ekronarongchai Supanuch,Srichatrapimuk Sirawat,Wongsirisin Pattama,Sangrajrang Suleeporn,Imsuwansri Thanarath,Kirdlarp Suppachok,Nualkaew Sureeporn,Sensorn Insee,Sawaengdee Waritta,Wichukchinda Nuanjun,Sungkanuparph Somnuek,Chantratita Wasun,Kunakorn Mongkol,Rojanamatin Jinda,Hongeng Suradej,Thitithanyanont Arunee
Funder
Mahidol University
National Research Council of Thailand
Ramathibodi Foundation
Reference5 articles.
1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Zhang;Lancet Infect Dis,2021
2. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile;Jara;N Engl J Med,2021
3. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection;Khoury;Nat Med,2021
4. Susceptibility of circulating SARS-CoV-2 variants to neutralization;Wang;N Engl J Med,2021
5. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada;Fisman;medRxiv,2021